Connor, Clark & Lunn Investment Management (CC&L)’s Mersana Therapeutics MRSN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,362	Closed	-$243K	–	1422
2023 Q1	$243K	Sell	2,362 -5,975	-72%	-$839K	﹤0.01%	1055
2022 Q4	$1.22M	Sell	8,337 -2,010	-19%	-$340K	0.01%	662
2022 Q3	$1.75M	Buy	+10,347	New	+$1.68M	0.01%	524
2021 Q1	–	Sell	-2,425	Closed	-$1.61M	–	1049
2020 Q4	$1.61M	Sell	2,425 -3,216	-57%	-$1.79M	0.01%	558
2020 Q3	$2.63M	Sell	5,641 -784	-12%	-$396K	0.02%	426
2020 Q2	$3.76M	Buy	+6,425	New	+$2.19M	0.03%	349

Other funds holding MRSN

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MRSN Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 2,362 shares — an estimated $243K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MRSN in Q2 2020 and held it in 6 quarters. The position peaked at $3.76M in Q2 2020. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 2,362 Mersana Therapeutics shares in Q2 2023, an estimated $243K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Mersana Therapeutics in Q2 2020 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Mersana Therapeutics position peaked at $3.76M in Q2 2020.
147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.